atezolizumab
roche
['nsclc', 'atezo', 'sclc']
os benefit was presented at acr for neoadjuvat atezo chemo, though small study data is assuring any thoughts?
mos: 55.8 months dfs: 80% #aacr2023 #aacr23 #nsclc
Master's in Pharmacy 
#gastrointestinalcancers #genitourinarycancers #solidtumors #IBD